Deutsch
English
Русский
ZOM / ZIM

Rheumatologie/Immunologie

ZIM (Zentrum für Innere Medizin)
Oberdürrbacher Str. 6
97080 Würzburg

Schwerpunktleiter:
Prof. Dr. med. H.-P. Tony


schmalzing_m@ukw.de

 

Lageplan-UKW_ZIM-ZOM

Lageplan-UKW_ZIM-Rheumatologie

Publikationsübersicht

Originalarbeiten H.-P. Tony:

  1. Tabares P, Berr S, Römer PS, Chuvpilo S, Matskevich AA, Tyrsin D, Fedotov Y, Einsele H, Tony HP, Hünig T. Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08.
    Eur J Immunol 2013. Dec 27. doi: 10.1002/eji.201343957 [Epub ahead of print]
    PMID:24374661 [PubMed - as supplied by publisher

  2. Witt M, Grunke M, Proft F, Baeuerle M, Aringer M, Burmester G, Chehab G, Fiehn C, Fischer-Betz R, Fleck M, Freivogel K, Haubitz M, Kötter I, Lovric S, Metzler C, Rubberth-Roth A, Schwarting A, Specker C, Tony HP, Unger L, Wassenberg S, Dörner T, Schulze-Koops H; Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID).; German Registry of Autoimmune Diseases (GRAID) Investigators.
    Lupus. 2013 Oct;22(11):1142-9. doi: 10.1177/0961203313503912.

  3. Albrecht K, Krüger K, Wollenhaupt J, Alten R, Backhaus M, Baerwald C, Bolten W, Braun J, Burkhardt H, Burmester GR, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Kuipers J, Krause A, Lorenz HM, Manger B, Nüßlein H, Pott HG, Rubbert-Roth A, Schneider M, Specker C, Schulze-Koops H, Tony HP, Wassenberg S, Müller-Ladner U.
    German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.
    Rheumatol Int. 2013 Aug 14. [Epub ahead of print]

  4. Behrens F, Tony HP, Alten R, Kleinert S, Scharbatke EC, Köhm M, Gnann H, Tams J, Greger G, Burkhardt H.
    Development and validation of a new disease activity score in 28 joints-based treatment response criterion for rheumatoid arthritis.
    Arthritis Care Res (Hoboken).
    2013 Oct;65(10):1608-16. doi: 10.1002/acr.22037.

  5. Aringer M, Tony HP. Systemic disease rheumatoid arthritis]. Z Rheumatol. 2012 Dec;71(10):840.

  6. Roll P, Ostermeier E, Haubitz M, Lovric S, Unger L, Holle J, Kötter I, Henes JC, Bergner R, Rubbert-Roth A, Specker C, Schulze-Koops H, Müller-Ladner U, Fleck M, Burmester GR, Hiepe F, Heitmann S, Aringer M, Fischer-Betz R, Dörner T, Tony HP. Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID). J Rheumatol. 2012 Nov;39(11):2153-6.

  7. Krüger K, Wollenhaupt J, Albrecht K, Alten R, Backhaus M, Baerwald C, Bolten W, Braun J, Burkhardt H, Burmester G, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Kuipers J, Krause A, Lorenz HM, Manger B, Nüßlein H, Pott HG, Rubbert-Roth A, Schneider M, Specker C, Schulze-Koops H, Tony HP, Wassenberg S, Müller-Ladner U; European League of Associations for Rheumatology (EULAR). German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm]. Z Rheumatol. 2012 Sep;71(7):592-603.

  8. Kleinert S, Tony HP. Rheumatic diseases with initial manifestations in middle age: gout, rheumatoid arthritis and ANCA-associated vasculitides]. Internist (Berl). 2012 Sep;53(9):1028-37.

  9. Ostermeier E, Roll P, Tony HP. Janus kinase inhibitors]. Z Rheumatol. 2012 Aug;71(6):473-8.

  10. Kleinert S, Roll P, Baumgaertner C, Himsel A, Mueller A, Fleck M, Feuchtenberger M, Jenett M, Tony HP. Renal perfusion in scleroderma patients assessed by microbubble-based contrast-enhanced ultrasound. Open Rheumatol J. 2012;6:50-3. doi

  11. Kleinert S, Tony HP, Krueger K, Detert J, Mielke F, Rockwitz K, Schwenke R, Burmester GR, Diel R, Feuchtenberger M, Kneitz C. Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γ release assays under real-life conditions. Ann Rheum Dis. 2012 Nov;71(11):1791-5.

  12. Palanichamy A, Muhammad K, Roll P, Kleinert S, Dörner T, Tony HP. Rituximab therapy leads to reduced imprints of receptor revision in immunoglobulin κ and λ light chains. J Rheumatol. 2012 Jun;39(6):1130-8

  13. Roll P, Muhammad K, Schumann M, Kleinert S, Tony HP. RF positivity has substantial influence on the peripheral memory B-cell compartment and its modulation by TNF inhibition. Scand J Rheumatol. 2012 May;41(3):180-5

  14. Aringer M, Burkhardt H, Burmester GR, Fischer-Betz R, Fleck M, Graninger W, Hiepe F, Jacobi AM, Kötter I, Lakomek HJ, Lorenz HM, Manger B, Schett G, Schmidt RE, Schneider M, Schulze-Koops H, Smolen JS, Specker C, Stoll T, Strangfeld A, Tony HP, Villiger PM, Voll R, Witte T, Dörner T. Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report. Lupus. 2012 Apr;21(4):386-401

  15. Kalden JR, Burkhardt H, Buss B, Donhauser-Gruber U, Erstling U, Gromnica-Ihle E, Karberg K, Karger T, Kneitz CH, Krause A, Krüger K, Lorenz HM, Müller-Ladner U, Rubbert-Roth A, Steffens-Korbanka P, Tony HP, Wendler J, Wollenhaupt J, Burmester G. Strategies for improved healthcare of people with the endemic disease rheumatism exemplified by rheumatoid arthritis]. Z Rheumatol. 2011 Oct;70(8):641-50.

  16. Rigby W, Tony HP, Oelke K, Combe B, Laster A, von Muhlen CA, Fisheleva E, Martin C, Travers H, Dummer W. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum. 2012 Feb;64(2):350-9.

  17. Lang VR, Englbrecht M, Rech J, Nüsslein H, Manger K, Schuch F, Tony HP, Fleck M, Manger B, Schett G, Zwerina J. Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Arthritis Rheum. 2012 Feb;64(2):350-

  18. Kleinert S, Tony HP, Krause A, Feuchtenberger M, Wassenberg S, Richter C, Röther E,     Spieler W, Gnann H, Wittig BM. Impact of patient and disease characteristics on   therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study. Rheumatol Int. 2012 Sep;32(9):2759-67

  19. Tony, HP., Burmester, G., et al. 2011. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 13(3):R75.

  20. Roll, P., Muhammad, K., Schumann, M., Kleinert, S., Einsele, H., Dorner, T., Tony, HP. 2011. In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum 63(5):1255-1264.

  21. Muhammad K., Roll, P., Seibold, T., Kleinert, S., Einsele, H., Dorner, T., Tony, HP. 2011. Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells. Ann Rheum Dis 70(8):1507-1510.

  22. Feuchtenberger, M., Kleinert, S., Schwab, S., Roll, P., Scharbatke, EC., Ostermeier, E., Voll, RE., Schafer, A., Tony, HP. 2011. Vaccination survey in patients with rheumatoid arthritis: a cross-sectional study. Rheumatol Int.

  23. Bittner S., Bobak, N., Feuchtenberger, M., Herrmann, AM., Gobel, K., Kinne, RW., Hansen, AJ., Budde T., Kleinschnitz, C., Frey, O., Tony, HP., Wiendl, H., Meuth, SG. 2011. Expression of K2P5.1 potassium channels on CD4+ T lymphocytes correlates with disease activity in rheumatoid arthritis patients. Arthritis Res Ther 13(1):R21

  24. Roll, P., Rubbert-Roth, A., Tony, HP. 2010. [Tocilizumab : What comes after TNF-blockers in clinical routine.]. Z Rheumatol 69:608-617.

  25. Mei, H E., Frolich, D., Giesecke, C., Loddenkemper, C., Reiter, K., Schmidt, S., Feist, E., Daridon, C., Tony, HP., Radbruch, A., Dorner, T. 2010. Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab. Blood 116(24):5181-5190

  26. Kraemer, DM., Tony, HP. 2010. Nuclear Pore Protein p62 Autoantibodies in Systemic Lupus Erythematosus. Open Rheumatol J 4:24-27

  27. Kleinert, S., Kurzai, O., Elias, J., Marten, K., Engelke, C., Feuchtenberger, M., Sandstede, J., Frosch, M.,
    Tony HP., Kneitz, C. 2010. Comparison of two interferon{gamma} release assays and tuberculin skin test for detecting latent tuberculosis in patients with immune-mediated inflammatory diseases. Ann Rheum Dis. 69(4):782-4

  28. Kleinert, S., Feuchtenberger, M., Tony, HP. 2010. [Systemic lupus erythematosus: A problem based approach.]. Internist (Berl) 51(8):1013-26

  29. Muhammad, K., Roll, P., Einsele, H., Dörner, T., Tony, HP. 2009. Delayed acquisition of somatic hypermutations in repopulated IGD+CD27+ memory B cell receptors after rituximab treatment. Arthritis Rheum 60(8):2284-93

  30. Roll. P., Tony. HP. 2009. [Anti-CD20 therapy in rheumatoid arthritis]. Z Rheumatol 68(5):370-9

  31. Feuchtenberger, M., Kneitz, C., Roll, P., Kleinert, S., Tony, HP. 2009. Sustained Remission After Combination Therapy with Rituximab and Etanercept in Two Patients with Rheumatoid Arthritis After TNF Failure: Case Report. Open Rheumatol J 3:9-13

  32. Roll, P., Tony, HP. 2009. [B-cell-targeted therapy in the treatment of autoimmune diseases]. Z Rheumatol 68(3):255-9

  33. Strangfeld, A., Hierse, F., Kekow, J., von Hinueber, U., Tony, HP., Dockhorn, R., Listing, J., Zink, A. 2009. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 68(12):1856-62.

  34. Feuchtenberger, M., Müller, S., Roll, P., Waschbisch, A., Schäfer, A., Kneitz, C., Wiendl, H., Tony, HP. 2008. Frequency of Regulatory T Cells is Not Affected by Transient B Cell Depletion Using Anti-CD20 Antibodies in Rheumatoid Arthritis. Open Rheumatol J 2:81-8.

  35. Palanichamy, A., Roll, P., Theiss, R., Dörner, T., Tony, HP. 2008. Modulation of molecular imprints in the antigen-experienced B cell repertoire by rituximab. Arthritis Rheum 58(12):3665-74

  36. Feuchtenberger, M., Kleinert, S., Tony, HP., Kneitz, C. 2008. Psoriatic arthritis: therapeutic principles. Clin Dermatol 26(5):460-3

  37. Emery, P., Keystone, E., Tony, HP., Cantagrel, A., van Vollenhoven, R., Sanchez, A., Alecock, E., Lee, J., Kremer, J. 2008. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67(11):1516-23.

  38. Roll, P., Dörner, T., Tony, HP. 2008. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 58(6):1566-75.

  39. Roll, P., Kleinert, S., Tony, HP. 2007. [Acute monarthritis]. MMW Fortschr Med 149(44):44-8

  40. Kleinert, S., Feuchtenberger, M., Kneitz, C., Tony, HP. 2007. Psoriatic arthritis: clinical spectrum and diagnostic procedures. Clin Dermatol 25(6):519-23

  41. Schmidt, E., Tony, HP., Bröcker, EB., Kneitz, C. 2007. Sun-induced life-threatening lupus nephritis. Ann N Y Acad Sci 1108:35-40

  42. Feuchtenberger, M., Kneitz, C., Tony, HP. 2007. [Cytokines]. Z Rheumatol 66(4):297-8, 300-3R

  43. oll, P., Palanichamy, A., Kneitz, C., Doerner, T., Tony, HP. 2006. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 54:2377-2386

  44. Braun J, Zochling J, Baraliakos X, Alten RH, Burmester GR, Grasedyck K, Brandt J, Haibel H, Hammer M, Krause A, Mielke F, Tony HP, Ebner W, Gomor B, Hermann J, Zeidler H, Beck E, Baumgaertner M, Sieper J. 2006. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomized controlled trial. Ann Rheum Dis.65:1147-53

  45. Reimer S, Hornlein A, Tony HP, Kraemer D, Oberuck S, Betz C, Puppe F, Kneitz C. 2006. Assessment of a case-based training system (d3web.Train) in rheumatology. Rheumatol Int. 24:1-7

  46. Feuchtenberger, M., Kneitz, C., Tony, HP. 2006. [Treatment of rheumatoid arthritis (RA) with anticytokines]. MMW Fortschr Med 148(42):44-5, 47

  47. Wollenhaupt, J., Alten, R., Burkhardt, H., Edelmann, E., Gromnica-Ihle, E., Krause, A., Krüger, K., Manger, B., Lorenz, H., Müller-Ladner, U., Nüsslein, H., Pott, HG., Tony, HP., Schneider, M. 2006. [Current therapeutic strategy for rheumatoid arthritis]. MMW Fortschr Med 148(42):38-42

  48. Kleinert, S., Tony, HP., Kneitz, C. 2006. [Systemic sclerosis]. Internist (Berl) 47(10):1051-61

  49. Kneitz, C., Tony, HP., Krüger, K. 2006. [NSAIDs and COX-2-inhibitors: current status]. Internist (Berl) 47(5):533-4, 536-8, 540

  50. Rouziere, AS., Kneitz, C., Palanichamy, A., Dörner, T., Tony, HP. 2005. Regeneration of the immunoglobulin heavy-chain repertoire after transient B cell depletion with an anti-CD20 antibody. Arthritis Res Ther 7, 714-724

  51. Kneitz C, Suerbaum S, Beer M, Muller J, Jahns R, Tony HP. 2005. Exacerbation of Whipple's disease associated with infliximab treatment. Scand J Rheumatol. 34:148-51

  52. Kraemer DM, Rath JC, Tony HP. 2005. Sarcoidosis type II and IgG autoantibodies-induced hemolysis in a 64-year-old woman. Eur J Intern Med. 16:536.

  53. Strobel P, Marino M, Feuchtenberger M, Rouziere AS, Tony HP, Wulbrand U, Forster R, Zettl A, Lee Harris N, Kreipe H, Laeng RH, Muller-Hermelink HK, Marx A. 2005. Micronodular thymoma: an epithelial tumour with abnormal chemokine expression setting the stage for lymphoma development. J Pathol. 207:72-82.

  54. Kneitz, C., Wilhelm, M., Tony, HP. 2004. Improvement of refractory rheumatoid arthritis after depletion of B cells. Scand J Rheumatol 33, 82-86

  55. Kraemer,DM., Tony, HP., Gattenlöhner, S., Müller, JG. 2004. Lymphoplasmacytic lymphoma in a patient with leaking silicone implant. Haematologica 89(4):ELT01

  56. Visan I., Goller M., Berberich I., Kneitz C., Tony H.-P. 2003 Pax-5 is a key regulator of the B cell restricted expression of the CD23a isoform Eur. J. Immunol . 33:1163-1173

  57. Krämer DM, Tony H.-P. Gattenlöhner S, Müller JG. 2003. Lymphoplasmacytic lymphoma in a patient with leaking silicone implant. Haematologica. 88(9):ELT30 (2003)

  58. Feuchtenberger M, Tony H.-P., Rouziere A.-S., Jacobi A., Dörner T., Kneitz C. and Starostik P. 2003 Semiquantitative and qualitative assessment of B-lymphocyte VH repertoire by a fluorescent multiplex PCR J Immunol Methods 276:121-7

  59. Wilhelm M., Kunzmann V., Eckstein S., Reimer P., Weissinger F., Ruediger Z., Tony H.-P. 2003. g/d T cells for immune therapy of patients with lymphoid malignancies. Blood 102:200-6

  60. Kraemer D., Kraus MR., Kneitz C., Tony H.-P. 2003. Nucleoporin p62 antibodies in a case of mixed connective tissue disease Clin Diagn Lab Immun 10:329-331

  61. Kneitz, C., Goebeler, M., Tony, HP. 2003. [Systemic lupus erythematosus]. Internist (Berl) 44(12):1557-71

  62. Kneitz, C., Wilhelm M., Tony H.-P. 2002. Effective B cell depletion with Rituximab in the treatment of autoimmune diseases. Immunobiology 206:519-527

  63. Kneitz C, Tony H.-P., Goller M, , Simon A, Stibbe C, König T, Serfling E, Avots A. 2002. The CD23b promotor is a target for NF-AT transcription factors in B-CLL cells. Biochim Biophys Acta 1588:41-47

  64. Hau M., Kneitz C., Tony H.-P., Keberle M., Jahns R., Jenett M. 2002. High resolution ultrasound detects a decrease in pannus vascularisation of small finger jonts in patients with rheumatoid arthritis receiving treatment with soluble tumour necrosis factor a receptor (etanercept) . Ann Rheum Dis 61:55-58

  65. Goller, M.; Kneitz, C.; Mehringer, C.; Müller, K.; Jelley-Gibbs, D.M.; Gosselin, E.J., Wilhelm M., Tony, H.P. 2002. Regulation of CD23 isoforms on B-chronic lymphocytic leukaemia. Leukemia Research 26:795-802

  66. Goebeler, ME., Kneitz, C., Beer, M., Goebeler, M., Tony, HP. 2002. [Spondyloarthritis]. Internist (Berl) 43(4):517-24, 526-30

  67. Keberle M., Tony H.-P., Hau M., Kessler C., Jahns R., Jenett M. 2001. Colour Doppler ultrasound of the nailbed: an objective tool for monitoring responses to vasodilatory treatment of connective tissue disorders? Rheumatology 40:954-955

  68. Kneitz, C., Tony, HP. 2001. [Rheumatoid arthritis--diagnosis and therapy]. MMW Fortschr Med 143(41):I-VIII

  69. Keberle M., Tony H.-P., Jahns R., Hau M., Haerten R., Jenett M. 2000. Assessment of microvascular changes in Raynaud´s phenomenon and connective tissue disease using colour-doppler ultrasound. Rheumatology 39:1206-1213

  70. Kunzmann V., Bauer E., Feurle J., Weißinger F., Tony H.-P., Wilhelm M. 2000. Stimulation of g/d T cells by aminobisphosphonates and induction of anti-plasma cell activity in multiple myeloma. Blood 96:384-92

  71. Reimer P., Weißinger F., Tony H.-P., Koniczek K., Wilhelm M. 2000. Persistent polyclonal B-cell lymphocytosis, an important differential diagnosis of B-CLL. Ann Hematol. 79:327-331

  72. Kneitz C., Goller M., Seggewiss R., Yaman A., Serfling E., Tony H.-P. 2000. Stat6 and the regulation of CD23 expression in B-chronic lymphocytic leukaemia. Leuk. Res. 24:331-337

  73. Jahns R., Naito J., Tony H.-P. Inselmann G. 1999. Atrial ejection force in systemic autoimmune disease. Cardiology 92:269-274

  74. Hau M., Schultz H., Tony H.-P., Keberle M., Jahns R., Haerten R., Jenett M. 1999. Evaluation of pannus and vascularization of metacarpophalangeal and proximal interphalangeal joints in rheumatoid arthritis by high resolution ultrasound (multi-D array). Arthr. Rheum. 42:2303-2308

  75. Jomaa H., Feurle J., Luhs K., Kunzmann V. Tony H.-P., Herderich M., Wilhelm M. 1999. Vgamma9/vdelta2 T cell activation induced by bacterial low molecular mass compounds depends on 1-deoxy-D-xylulose 5-phosphate pathway of isoprenoid biosynthesis. FEMS Imunol.Med.Microbiol. 25:371-378

  76. Schultz H., Krenn V., Tony H.-P. 1999. Oligoarthritis mediated by tumor-specific T lymphocytes in renal-cell carcinoma. N Engl.J.Med. 341:290-291 (1999)

  77. Kneitz C., Goller M., Wilhelm M., Mehringer C., Wohlleben G., Schimpl A., Tony H.-P. 1999. Inhibition of T cell/B cell interaction by B-CLL cells. Leukemia 13:98-104

  78. Krenn V., Schedel J, Döring A., Huppertz H.-I., Gohlke F., Tony H.-P., Vollmers H.P., Müller-Hermelink H.K.1997. Endothelial cells are the major source of sICAM-1 in rheumatoid synovial tissue. Rheumatol. Int. 17:17-27

  79. Wiesner J., Jomaa H., Wilhelm M., Tony H.-P., Kremsner PG, Horrocks P., Lanzer M. 1997. Host cell factor CD59 restricts complement lysis of plasmodium falciparum infected erythrocytes. Eur. J. Immunol. 27:2708-2713

  80. Wilhelm, M., Tony, HP., Rueckle-Lanz, H., Wilms, K. 1997. First-line therapy of advanced chronic lymphocytic leukemia. Leukemia 11 Suppl 2:S14-8.

  81. Schmidt E., Bastian B., Dummer R., Tony H.-P., Bröcker E.-B., Zillikens D. 1996. Detection of elevated levels of IL-4, IL-6 and IL-10 in blister fluid of bullous pemphigoid. Arch.Dermatol.Res. 288: 353-357

  82. Schuh K., Avots A., Tony H.-P., Serfling E., Kneitz C. 1996. Nuclear NF-ATp is a hallmark of unstimulated B cells from B-CLL patients. Leuk. Lymphoma 23:583-592

  83. Kneitz, C., Wilhelm, M., Kraus, MR., Tony, HP., Tschammler, A., Jany, B. 1995. [Sarcoidosis in monozygotic twins]. Dtsch Med Wochenschr 120(24):867-73.

  84. Tony, H.-P., Shen,B., Reusch,P., Sebald W. 1994. Design of human IL-4 antagonists inhibiting highly efficient IL-4 and IL-13 dependent responses in T- and B-cells. Eur.J.Biochem. 225: 659-665

  85. Wilhelm M and H.-P. Tony. 1994. An in vitro model for the expansion of vg9d2-T lymphocytes during development. Scand J Immunol 40: 521-528

  86. Jakob F., Seufert J., Sarrazin C., Schneider D., Köhrle and H.-P. Tony.1994. Topoisomerase I-inhibition enhances vitamin D-responsive expression of the receptor for lipopolysaccharide binding protein CD14. BBRC 199:531-539

  87. Wilhelm, M., Tony, HP., Rieber, P. 1994. [Sensible diagnosis in suspected immune deficiency]. Fortschr Med 112(28):383-7.

  88. Wilhelm, M., Tony, HP. 1994. [Treatment of patients with acquired (non-HIV) immune deficiencies]. Fortschr Med 112(9):117-21.

  89. Blum C., Zillikens D., Tony H.-P., Hartmann A. und G.Burg. 1993. Der lösliche Interleukin-2-Rezeptor als Aktivitätsparameter im Serum von systemischem und diskoidem Lupus erythematodes. Hautarzt 44:290-295

  90. Tony, H.-P., Brückner A.and M.Wilhelm. 1993. Differential signal requirement for upregulation of HLA-class II molecules in lymphoma B cells. Hematol. Pathol. 7:79-90

  91. Kruse N., Shen B., Arnold S., Tony H.-P., Müller T. and W. Sebald. 1993. Two distinct functional sites of human interleukin-4 are identified by variants impaired in either receptor binding or receptor activation. EMBO Journal 12:5121-5129

  92. Wilhelm M., P. Meyer, C. Bartram, H.-P. Tony, R. Dummer, F. Nestle, G. Burg, K. Wilms. 1992. g/d-receptor expressing T-cell clones from a cutaneous T-cell lymphoma suppress hematopoiesis.  Ann. Hematol. 65:111-115

  93. Wilhelm M., Dünninger P., Rüppel R., Tony H.-P., Wilms K., Klaiber B. 1992. Failure to detect any effect of amalgam restorations on peripheral blood lymphocyte populations. Clinical Invest. 70:728-734

  94. Kruse N., H.-P. Tony and W. Sebald. 1992. Conversion of interleukin- 4 into a high affinity antagonist by a single amino acid replacement. EMBO Journal 11:3237-3244

  95. Jakob F., Tony H.-P., H.H.Thole. 1992. Immunochemical detection of oestradiol receptor proteins in cell lines derived from the lymphatic system and the hematopoietic system: variability of specific hormone binding in vitro. J. Endocrinology 134:397-404

  96. Wilhelm M., Dünninger P., Rüppel R., Tony H.-P., Wilms K., Klaiber B. 1991. Einfluß von Amalgam auf Zellen des Immunsystems. Dtsch. Zahnärztl. Z. 46, 544-547

  97. Tony, H.-P., T. Lehrnbecher, H. Merz, W. Sebald and M.Wilhelm. 1991. Regulation of IL-4 responsiveness in lymphoma B cells. Leukemia Research 15:911-919

  98. Wilhelm, M. and H.-P. Tony. 1990. Characterization of an acute lymphoblastic leukemia expressing the gamma/delta T cell receptor. Blut 61:213-216

  99. Gosselin, E.J., H.-P. Tony and D. C.Parker. 1988. Characterization of antigen processing and presentation by resting B lymphocytes. J.Immunol. 140: 1408-1413

  100. Whalen, B.J., H.-P. Tony and D. C.Parker. 1988. Characterization of the effector mechanism of help for antigen-presenting and bystander resting B cell growth mediated by IA-restricted Th2 helper T cell lines. J.Immunol. 141: 2230-2239

  101. Lichtman A.H., H.-P. Tony, D.C. Parker, A.K.Abbas. 1987. Antigen presentation by hapten-specific B lymphocytes. IV. Comparative ability of B cells to present specific antigen and anti-immunoglobulin antibody. J.Immunol. 138:2822-2825

  102. Tony, H.-P., D.C. Parker 1985. Major histocompatibility complex -restricted, polyclonal B-cell responses resulting from helper T-cell recognition of anti-immunoglobulin presented by small B lymphocytes. J. Exp. Med. 161: 223-241

  103. Tony, H.-P., N.E. Phillips, D.C. Parker. 1985. Role of membrane immuno-globulin (Ig) crosslinking in membrane Ig-mediated major histocompatibility restricted T-cell B-cell cooperation. J. Exp. Med. 162: 1695-1708

  104. Parker, DC., Tony, HP. 1984. Anti-Ig as a model for MHC-restricted help. Ann Immunol (Paris) 135D(1):89-91.

  105. Tony, H.-P. and A.Schimpl 1980. Stimulation of murine B cells with anti-Ig antibodies: dominance of a negative signal mediated by the Fc receptor. Eur. J. Immunol. 10: 726-729